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High-dose gallium-67 therapy in patients with relapsed acute leukaemia: a
feasibility study
AR Jonkhoffi, MABD Plaizier2, GJ Ossenkoppelel, GJJ Teule2 and PC Huijgens'
Free University Hospital, Departments of'Haematology and 2Nuclear medicine, Department ofHaematology, Br 238, de
Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Summary Gallium-67 (67Ga) accumulates in malignant tissues via the transferrin receptor without need for a
monoclonal antibody and emits cytotoxic low-energy electrons. In this study we investigated the feasibility,
pharmacokinetics, toxicity and preliminary efficiency of high-dose 67Ga injected intravenously (i.v.) in patients
with acute leukaemia not responding to conventional therapy. Twelve doses of 36-105mCi of Gallium67
citrate were administered as a push injection to eight patients with resistant leukaemia in a pilot study. All five
patients with acute myeloid leukaemia (AML) and three patients with acute lymphoblastic leukaemia (ALL)
had resistant disease or resistant relapse. No (sub)acute toxicity was observed. Independent of the
administered dose, whole-blood radioactivity levels 10 min after administration measured only 1.25 ± 1.39 jsCi
ml-', indicating a large volume of distribution. Urine excretion in the first 24 h ranged from 18% to 51.5%
(median 29.5%) of the administered dose. Cellular uptake of 67Ga was less than in previous in vitro studies.
Whole-body radiation dose was estimated to be 0.25 ± 0.03 cGy mCi-'. Red marrow dose was estimated to be
between 0.18 ± 0.02 and 0.97 ± 0.12 cGy mCin'. One definite response was observed in an ALL patient with
disappearance of skin lesions, normalisation of the enlarged spleen and profound leucopenia. Three other
patients showed transient reductions in white blood cell counts without disappearance of blasts from the
peripheral blood. We conclude that high-dose i.v. 67Ga can be safely administered but that the uptake of 67Ga
in blast cells must increase to make 67Ga therapeutically useful in patients with relapsed leukaemia.
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Although the initial remission rate of acute leukaemia in
adults is high (70-80%), a considerable portion of patients
eventually die of their disease (Rohatiner et al., 1990).
Therefore, new treatment modalities have to be explored.
The idea of therapy with a radionuclide that accumulates in
the target tumour cell by itself is appealing. Recently, pro-
mising results were reported from radioimmunotherapy with
a '31iodine-labelled anti-CD33 monoclonal antibody (MAb)
in patients with relapsed or refractory myeloid leukaemia
(AML) (Appelbaum et al., 1990; Schwartz et al., 1993).
However, problems related to MAb-mediated radiotherapy
include adverse reactions caused by the administration of
foreign protein and the forming of human anti-mouse
antibodies (HAMA), precluding repeated cycles of therapy
(Rosen and Kuzel, 1993).
We are currently investigating the therapeutic potential of
the radionuclide gallium-67 (67Ga), which accumulates in
malignant tissues via the transferrin receptor (Nelson et al.,
1972; Anghieri et al., 1977; Chitambar et al., 1986; Leeuwen-
Stok et al., 1993). We have shown that 67Ga is cytotoxic in
vitro to human HL60 myeloid cells and U937 and U715
lymphoid cells (Jonkhoff et al., 1993, 1994; Leeuwen-Stok et
al., 1993). However, the relative biological effectiveness
(RBE) of67Ga was approximately 1.0, indicating a rather low
effectiveness for cell kill of its low-energy electron emissions,
which confirmed earlier studies (Hofer et al., 1975; Jonkhoff
et al., 1994). Radionuclides mentioned as candidates for
radionuclide therapy are generally beta-emitting nuclides in-
cluding yttrium-90, iodine-131, rubidium-86, phosphorus-32,
indium-114m, samarium-153 (Coursey et al., 1991; Rao and
Howell, 1993). Auger electron emitters, such as ['25I]IUdR
have favourable properties, but are considered too toxic for
in vivo use (Makrigiorgos et al., 1990). The reason 67Ga was
never considered for therapy might be because of insufficient
data on its effectiveness, its low-energy electron emissions,
precise intracellular localisation and heterogeneous uptake.
In vitro blast cells of some AML patients accumulate 67Ga
strongly, and after incubation with 80IsCi ml-' 67Ga,
clonogenic survival was reduced more than 90% compared
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with control cells. In some blast cells clonogenic growth was
completely abolished after only 201sCi ml l 67Ga (Jonkhoff et
al., 1995). Some of the relative ineffectiveness of 67Ga for cell
kill might be compensated by a high in vivo cellular uptake of
67Ga and favourable pharmacokinetic data.
In this study we report the first in vivo data concerning
toxicity and pharmacokinetics and preliminary efficacy of
67Ga in eight patients with resistant acute leukaemia.
Materials and methods
Patients
Patients with end stage acute leukaemia were entered into the
study after giving informed consent according to the Declara-
tion of Helsinki. The study was approved by the ethical
committee of the Free University. Five patients with acute
myelogenous leukaemia (AML) and three patients with acute
lymphoblastic leukaemia (ALL) were included. All patients
had a WHO performance status of 0 or 1. No patient had
pre-existent cardiac, pulmonary or renal disease. Supportive
care medication in most patients included ciprofloxacin,
fluconazol, ranitidine, tranexamic acid, and transfusion of
blood products. The only cytostatic co-medication allowed
was prednisone or dexamethasone in ALL and hydroxyurea
in AML patients, in order to control peripheral blast counts.
67Ga
Carrier-free 67Ga was obtained from Mallinckrodt Diagnos-
tics (Petten, The Netherlands) as 67Ga chloride. 67Ga citrate
for intravenous injection, with a low citrate concentration,
was prepared as described previously (Jonkhoff et al., 1993).
67Ga citrate was given in a volume of 10 ml as a rapid
intravenous push, except in patient 5 who was given a second
injection of 67Ga as a 1 h infusion in order to study urinary
excretion and transferrin binding. Radiation safety precau-
tions, including rules for hospitalisation on a nuclear
medicine unit, were in accordance with accepted guidelines
(National Council on Radiation Protection, 1970).Gallium-67 in acute leukaemia
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The lowest dose level was based on experience in lym-
phoma patients, who suffered no side-effects other than
myelosuppression after administration of 40-60mCi 67Ga
i.v. (Huijgens et al., 1993). Before and biweekly after 67Ga
administration, whole blood cell counts were determined.
Liver enzymes and renal function were tested weekly.
Transferrin receptor
The percentage of transferrin receptor-positive leukaemia
blasts (5000 events) were analysed on a FACScan flow
cytometer (Becton Dickinson). A FITC-conjugated mouse
anti-human monoclonal antibody was used (Dako-CD71,
Ber-T9; Glostrup, Denmark). An irrelevant IgGI was used as
isotype control.
Cellular uptake of67Ga
Whole blood samples were drawn from the patient by
venipuncture 10min, 60 min and 24 h after 67Ga administra-
tion and put on ice immediately. After lysing erythrocytes
using three drops of lysing solution the cellular 67Ga uptake
and cellular 67Ga content was determined as described
previously (Jonkhoff et al., 1995). All radioactivity values
were corrected for physical decay (at t = 0).
Pharmacokinetics
Radioactivity of whole blood samples was measured 10 min,
60 min and 24 h after injection of 67Ga. The first 24 h after
injection the urine was collected to measure the renal excre-
tion of 67Ga. In one patient plasma samples on more time
points were measured. In this patient (patient 8) the area
under the curve (AUC) of 67Ga was analysed by Topfit 2.0,
using a non-compartmental model (Tanswell et al., 1993).
Scintigraphy
Twenty-four hours after 67Ga administration a whole body
scintigraph was performed with a dual-head gamma camera
and medium-energy collimators (ADAC Laboratories, Mil-
pitas, CA, USA).
Dosimetry
In six patients (seven complete measurements) the blood and
whole body data were used for red marrow dose calculations.
The residence times of 67Ga in the blood and whole body
were derived from numerical integration of the blood and
urinary time activity curves. After 24 h we assumed no
biological clearance and only physical decay of 67Ga.
Table I Patient
With approach A the activity in the whole body was
assumed to be homogeneously distributed (Plaizier et al.,
1994a,b). With approach B the activity in the whole body
was assumed to be equally divided between the remainder of
the body and the skeleton. The latter approach was used to
illustrate the theoretical 'maximal' effect of specific bone
uptake on the red marrow dose.
The activity in the red marrow and blood was assumed to
be equal (Siegel et al., 1990). Specific uptake in the red
marrow is neglected because of lack of information on red
marrow kinetics. Whole-body radiation dose was estimated
from the whole body residence time.
Whole body and red marrow dose were calculated accord-
ing to MIRDDOSE2 (Watson and Stabin, 1984). The kinetic
and dosimetric data were compared with the ICRP-53 (Inter-
national Commission on Radiation Protection, 1987) and
MIRDDOSE2 standard.
Statistics
Statistical analysis was performed with Stat-Graphics 2.6
statistical computer program.
Results
Toxicity
Patient characteristics are presented in Table I. All patients
had resistant or relapsed disease, and there were no curative
options left. Serum transferrin and ferritin levels were
1.83 ±0.19g1-' (range 1.59-2.04) and 5269± 3783 sgl-l
(range 2060-12 444) respectively.
In total, 12 doses of 67Ga were delivered i.v. Doses ranged
from 36-105 mCi. None of the patients was admitted for
more than 24 h. No acute toxicity was observed. Two
patients noted a slight fruity flavour. One patient noted
increased bleeding tendency and muscle pains in the 4 days
following 60mCi 67Ga. However, no objective increase in
bleeding tendency was observed and muscle pains did not
occur after a second administration of 60 mCi 67Ga in the
same patient.
No change in kidney or liver function was observed. Levels
of lactate dehydrogenase (LDH) varied with disease activity,
and were not correlated with 67Ga administration.
Haematological effects were restricted to those on blast
counts.
Pharmacokinetics
Table II shows the pharmacokinetics after 10 min. Most
patients had whole blood levels between 1.0 and 1.5fiCi
characteristics including age, sex, transferrin receptor density (CD71),
previous therapy and disease status
Patient CD71
no. Age MIF Diagnosis (%) Previous treatment Status
1 27 F AML, a,b,c,ABMT,d Second relapse
M2
2 45 F AML, 23 a,b,c,ABMT Second relapse
Ml
3 62 F AML, 18 a(2 x),c(2 x),b Resistant relapse
Ml
4 58 F AML, 43 a,b,c, + cyclosporin A Resistant disease
M4
5 60 F AML, 79 a(2 x),c Resistant relapse
M5b
6 22 M ALL 3 e,b,d Resistant disease
7 32 F ALL 68 e,f,g,h Second relapsea
8 50 M ALL 28 e,f,ABMT First relapse
Treatments: a, daunorubicin/ARA-C; b, amsacrine/ARA-C; c, mitoxantrone/VP16 (eto-
poside); d, VP16 (3000mgm-2) + melphalan (100mgmr-2); e, daunorubicin/vincristine/
asparaiginase/prednisone; f, 6-mercaptopurine/methotrexate/ARA-C/ cyclophosphamide; g,
vincristine/doxorubicin/dexamethasone; h, ARA-C/VP16. ABMT, autologous bone marrow
transplantation busulphan 16 mgkg-' + cyclophosphamide. aSystemic + leptomeningeal
relapse.
154
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Table II Pharmacokinetics
67Ga 67Ga 10 min 60 min 24 h Urine Urine
Patient dose dose p.i. p.i. p.i. 24 h 24 h
no. (mCi) (mCim-2) (01Ciml-') (KaCiml-') (MCiml-') (mCi) dose (%)
1 36.0 20 0.82 0.31 0.09 NA
62.0 34 0.45 0.23 0.09 NA
2 59.6 31 1.19 0.58 0.13 16.3 27
3 54.9 34 1.00 0.45 0.17 20.7 38
77.0 48 1.25 0.55 0.29 35.9 46.5
4 82.0 48 1.50 0.76 0.27 32.9 40
5 78.2 45 4.47 1.42 0.27 14.0 18
62.6a 36 NA NA NA 16.4 26
83.9 48 1.86 0.92 NA 16.3 19.5
6 82.8 44 1.68 0.68 0.24 42.7 51.5
7 53.2 27 4.48 3.00 0.6 NA
8 105.0 47 0.80 0.44 0.06 31.0 29.5
Median 20.7 29.5
s.d. 10.6 11.7
Pharmacokinetic data, including total administered dose ofgallium-67 citrate (mCi), dose per square
metre body surface (mCi m-2), whole-blood 67Ga radioactivity 10 min, 60 min and 24 h post injection
(pCi ml-'), total67Ga urineexcretion in thefirst 24 hpostinjection(mCi)andurineexcretion aspercentage
ofthe injected dose [dose (%)]. All radioactivity values are corrected for physical decay (at t = 0). Median
value and s.d. are given for the urinary excretion. a67Ga administered as 1 h infusion. NA, not available.
ml-', with two patients (5 and 6) reaching higher levels of
4.5g.Ci ml-'. One h post injection (p.i.) blood levels were
approximately halved, compared with 10min p.i. The 24h
blood levels were approximately 30% of the 1 h blood levels.
One patient (patient 8) was more extensively monitored for
plasma levels (Figure 1). A steep decrease in plasma radioac-
tivity level was noted in the first minutes after administration.
Pharmacokinetic data calculated in this patient are given in
the legend of Figure 1.
Of the 12 administrations of 67Ga, urine excretion was
measured on nine occasions. The median urine excretion of
67Ga in the first 24 h p.i. was 29.5% (range 18 -51%) of the
administered dose. In three patients the first 0-6 h urine
portion was collected separately. These collections contained
22.1 mCi (27% of injected dose) in patient 4, 32.8 mCi
(39.6% of injected dose) in patient 6 and 17.5 mCi (16.6% of
injected dose) in patient 8.
Cellular uptake and dosimetry
Cellular uptake values of 11 6'Ga administrations were
1.57 ± 2.67% (range 0.07-9.00%), 1.57 ± 2.71% (range
0.05-8.70%) and 1.86 ± 2.00% (range 0.05-5.18%), 10 min,
60 min and 24 h after injection respectively (median value ±
s.d.).
Cellular 67Ga content values of 11 67Ga administrations
were 1.73 ± 19.40 (range 0.08-66.22) 10-3pCi per cell,
0.89 ± 4.97 (range 0.04-17.15) 10-3pCi cell-' and 0.27 ±
1.25 (range 0.02-3.41) 10-3pCi per cell, 10min, 60 min and
24 h after injection respectively (median value ± s.d.).
The whole-body residence time was estimated to be
90.89 ± 12.40 h compared with 88.56 h calculated according
to ICRP-53. We calculated a red marrow residence time of
0.41 ± 0.16 h, which differed considerably from the com-
parable ICRP-53 value of 4.78 h.
The whole body dose was estimated to be 0.25 ± 0.03 cGy
mCi-', which compares well with MIRD/ICRP-53 calcula-
tions of 0.24 cGy mCi-'. The red marrow dose depended on
whether a homogeneous distribution was expected; approach
A, 0.18 ± 0.02 cGy mCi-' or 50% accumulation of the total
activity in the skeleton was assumed; approach B, 0.97 ± 0.12
cGy mCi-'. The comparable MIRD/ICRP-53 value for the
red marrow dose was 0.70 cGy mCi-'.
Scintigraphy
Figure 2a shows a 5 mCi diagnostic 67Ga scan without
abnormalities; Figure 2b shows a 67Ga scan in a non-
Hodgkin's lymphoma patient after high-dose gallium-67 cit-
rate administration; and Figure 2c shows a similar scan in
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Figure 1 The curve shows the course of plasma 67Ga radioac-
tivity values (juCi ml-', corrected for physical decay) in time after
intravenous injection (h) of patient 8. Area under the curve,
11.46ACi 1- h-; total clearance, 145 ml min-'; mean residence
time, 18 h; volume of distribution, 365 1; terminal half-life, 40.3 h.
Figure 2 Whole body 67Ga scintigraphs of diagnostic scan with a
normal distribution 72 h after administration of 5 mCi 67Ga (a),
scintigraphs 24 h after therapeutic administrations of 100 mCi
67Ga in a patient with non-Hodgkin's lymphoma (b) and patient
8 with acute myeloid leukaemia (c). ADAC, Genesys dual head
system.
patient 8. The figure shows a representative image of a
scintigraphy study in a leukaemia patient 24 h after a
therapeutic dose of 105 mCi of 67Ga (patient 8). The marked
increase of 67Ga accumulation in the skeleton is notable.
Decreased activity is seen in the liver, and there is almost
complete absence of bowel excretion.
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Response
Objective judgement of response was hindered by the con-
comitant anti-leukaemic medication (hydroxyurea or cor-
ticosteroid). In Figure 3 white blood cell counts (WBC) in all
patients are presented in relation to the medication. AML
patients 3 and 5 showed a reduction in WBC following
administration of 67Ga. Normal WBC values were only
reached in patient 5, although the white blood cell
differentiation still showed the presence of 52% blast cells.
Furthermore, notable in this patient was the normalisation of
the serum LDH from 1119 U1I (N=250U1V') to 155U
1-'. The response, however, was short-lived as the WBC
increased 15 days after the second administration.
Of the ALL patients, patient 6 had a definite response with
WBC decreasing <0.1 x 1091-', 20 days p.i., normalisation
of the enlarged spleen, which ranged 7 cm beneath the left
costal margin and disappearance of skin lesions. Patient 8
had an initial rise in WBC up to over 200 x IO' 1` in 4 days.
Dexamethasone was started followed by a steep decrease in
WBC. However, it is unlikely that dexamethasone caused the
ensuing leucopenia, which was probably an effect of the 67Ga
administration.
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Figure 3 Course of white blood cell counts in all patients during a varying observation period. The administration of high dose
gallium-67 citrate is indicated. Concomitant medication and its dose is given. In patient 5 the platelet counts are indicated as well
(dotted line).
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In the present study eight patients with relapsed and/or
resistant acute leukaemia received in total 12 doses of high-
dose 67Ga. No acute side-effects were observed nor any extra-
haematological effect. Myelotoxicity is considered to be the
major and dose-limiting toxicity in most radionuclide
therapies in lymphoma patients (Kaminski et al., 1993; Press
et al., 1993). In our study myelotoxicity was apparent by the
(transient) effect on blast cells but not in changes in eryth-
rocyte and platelet requirements.
Whole blood levels of radioactivity were unexpectedly low,
with values in six patients between 0.80 and 1.86pCimh-'
10min after administration. We expected higher levels as
67Ga is temporarily confined to the plasma compartment by
prompt binding to transferrin (Vallabhajosula et al., 1980).
For instance, in patient 8, with an estimated blood volume of
7.5 1 and who received 105 mCi, one would have expected an
initial blood level of 14ILCi ml-' instead of the 0.80yICi ml1-
we found. Low plasma 67Ga levels are described following
chemotherapy (Shephton and Martin, 1980) but this was not
the case in patient 8. The observed steep initial decrease in
plasma or blood 67Ga levels seem to disagree with phar-
macokinetic data of 67Ga that describes a short-lived and a
long-lived component with a biological half-life of approx-
imately 30 h and 613 ± 83 h respectively (Cloutier et al.,
1988). The urine excretion was unexpectedly high with a
median value of 29.5% (range 18-51.5%) of the injected
dose excreted in the first 24 h. The urinary excretion seems
larger than the 26% of the injected dose of67Ga in the first 7
days after injection that Nelson et al. (1972) observed in 23
patients.
Pharmacokinetic data of non-radioactive gallium nitrate
report 24 h urinary excretion of 15-72% after a bolus injec-
tion (Hall et al., 1979; Kelsen et al., 1980). No difference in
urinary excretion between bolus injection or 1 h infusion was
observed in patient 5, who served as her own control. The
observed pharmacokinetic differences could be related to the
concomitant medication or differences in patient group. The
iron status of our patients, who received frequent blood
transfusions, could have been of influence. Another pos-
sibility is that our low-citrate formula of67Ga influenced our
data, as gallium-67 citrate can form multinucleate polymeric
forms, gallium hydroxides or bind to serum proteins other
than transferrin (Larson et al., 1978). We tried to measure
the portion of 67Ga-Trf in the plasma samples by high-
performance liquid chromatography (HPLC), but could not
validate sufficiently the stability of the 67Ga-Trf binding
during the procedure, as free gallium-67 citrate complexes
with the silica of the column.
The uptake of67Ga in the blast cells was approximately 40
times less than in our in vitro experiments (Jonkhoff et al.,
1993, 1995; Leeuwen-Stok et al., 1993). This rather low
cellular 67Ga uptake might be explained by insufficient Trf-
receptor expression on blast cells, the relatively high Trf
concentration in the blood/bone marrow compartment,
which inhibits the uptake of 67Ga in the cell (Leeuwen-Stok
et al., 1993) or the low blood levels of 67Ga. No apparent
correlation was found between Trf receptor (CD71) expres-
sion, or 67Ga uptake in blast cells and in vivo response.
Our dosimetric calculations show similar whole body
retention times between this study and ICRP-53. The seem-
ing contradiction between a larger than expected urinary
excretion and similar residence times to ICRP values can be
explained by the neglect in our study of biological clearance
after 24 h. The calculated activity in red marrow however is
considerably lower than the red marrow activity suggested by
the ICRP-53. The red marrow absorbed dose based on the
ICRP-53 lies between red marrow absorbed dose calculations
with assumed different skeleton activities (approach A or
B). For individual patients the total red marrow dose
varied between 10-17cGy (approach A) and 52-1lOcGy
(approach B) depending on the chosen approach (data not
shown). As we observed at least one definite clinical res-
ponse, approach B seems more realistic. It is also possible
that the absorbed whole body and red marrow doses are
underestimated because microdosimetry was not taken into
account (van Dieren, 1993). Furthermore, we cannot exclude
the possibility that bone marrow blast cells had a higher
uptake of 67Ga than the peripheral blasts, as the minimal
67Ga content in the cells with only a few disintegrations in a
million cells is not likely to result in the observed clinical
response.
The body distribution measured by scintigraphy showed an
abnormal pattern, compared with high-dose 67Ga administra-
tion in lymphoma patients (Huijgens et al., 1993). The
skeleton was imaged more clearly and liver, spleen and bowel
less intensively. We cannot exclude the possibility that the
distribution in the skeleton is caused by the bone-seeking
properties of 67Ga (Ando et al., 1989) or uptake in bone
marrow blasts. More likely, however, the distribution in the
skeleton is due to additional factors such as iron overload.
Engelstad et al. (1982) described a similar 67Ga distribution
in patients with multiple red cell transfusions.
Responses are difficult to interpret with concomitant anti-
leukaemic medication. Two AML patients seemed to respond
with decreasing WBC after 67Ga administration (patients 3
and 5), but these responses seem to be short lived. Blast cells
remained in peripheral blood smears. Of the ALL patients,
one had a definite response with disappearance of skin
lesions and normalisation of the enlarged spleen. Profound
leucopenia (WBC<0.1 x I0 1') was encountered from 15
days p.i. onwards, until death 2 months later. Another ALL
patient (patient 8) had a very steep decrease in WBC, with
disappearance of blast cells, following *dexamethasone
medication. This decrease in WBC might be caused by the
67Ga administration, as radionuclide therapy is known to
exert its effect only after several days. In total, we observed
one definite response (13%) and three possible responses
(38%) out of eight patients.
Our conclusion is that high-dose 67Ga therapy is well
tolerated, but cellular 67Ga uptake is relatively low. Phar-
macokinetic data suggest a large proportion of non-
transferrin-bound 67Ga, influencing urine excretion, body
distribution and possibly cellular uptake. Nevertheless, tran-
sient responses and one definite response were noted.
Therefore, we feel that if cellular 67Ga uptake can be
enhanced by additional measures, such as desferrioxamine or
iron-dextran administration (Shani et al., 1986), high-dose
67Ga therapy might be useful in leukaemia patients.
Acknowledgements
This study was supported by a grant from the Dutch Cancer Society
(IKA 91-07).
References
ANDO A, ANDO I, HIRAKI T AND HISADA K. (1989). Relation
between the location ofelements in the periodic table and various
organ-uptake rates. Nucl. Med. Biol., 16, 57-80.
ANGHIERI LJ AND HEIDBREDER M. (1977). On the mechanism of
accumulation of 6'Ga by tumors. Oncology, 34, 74-77.
APPELBAUM FR, MATTHEWS DC, EARY J, FISHER L, PRESS 0,
MARTIN P, DURACK L, BADGER C AND BERNSTEIN I. (1990).
Use of radioiodinated anti-CD33 antibody to augment marrow
irradiation prior to marrow transplantation for AML. Proc. Am.
Soc. Hematol., 76, 526a.
CHITAMBAR CR AND SELIGMAN PA. (1986). Effects of different
transferrin forms on transferrin receptor expression, iron uptake,
and cellular proliferation of human leukaemic HL60 cells. J. Clin.
Invest., 78, 1538-1546.
CLOUTIER RJ, WATSON EE, HAYES RL, NELSON B AND SMITH EM.
(1988). Report No. 2: Gallium-66-, Gallium-67-, Gallium-68-,
and Gallium-72-citrate. In: MIRD Primer, for Absorbed Dose
Calculations, Loevinger R, Budinger ThF and Watson EE (eds),
pp. 40-42, Society for Nuclear Medicine: New York.Gallium-67 in acutelhukaemia
AR Jonkhoff etal
1 RAr.
COURSEY BM, CALHOUN JM, CESSNA J, GOLAS DB, GRAY DH,
HOPPES DD, SCHIMA FJ AND UNTERWEGER MP. (1991).
National standards for diagnostic and therapeutic nuclides. In:
Fifth International Radiopharmaceutical Dosimetry Symposium.
Proceedings of a conference held at Oak Ridge (TN): 7-10 May,
1991. pp. 152-143.
ENGELSTAD B, LUK SS AND HATTNER RS. (1982). Altered 67Ga
distribution in patients with multiple red blood cell transfusions.
AJR, 139, 755-759.
HALL SW, YEUNG K, BENJAMIN RS, STEWART D, VALDIVIESO M,
BEDIKIAN AY AND LOO TL. (1979). Kinetics of Gallium nitrate,
a new anticancer agent. Clin. Pharmacol. Ther., 25, 82-87.
HOFER KG, HARRIS CR AND SMITH JM. (1975). Radiotoxicity of
intracellular 67-Ga, 125-I and 3-H nuclear versus cytoplasmic
radiation effects in murine L1210 leukaemia. Int. J. Radiat. Biol.,
28, 225-241.
HUIJGENS PC, JONKHOFF AR, HOEKSTRA OS, OSSENKOPPELE GJ
AND TEULE GJJ. (1993). Therapeutic potential of intravenous
67-Gallium in non-Hodgkin's lymphoma. Eur. J. Haematol., 51,
206-208.
INTERNATIONAL COMMISSION ON RADIATION PROTECTION
(ICRP). (1987). Radiation dose to patients from radiophar-
maceuticals. ICRP publication no. 53. Annu. ICRP, 18, 1-4.
JONKHOFF AR, HUIJGENS, PC, VERSTEEGH RT, VAN DIEREN EB,
OSSENKOPPELE GJ, MARTENS HJM AND TEULE, GJJ. (1993).
Gallium-67 radiotoxicity in human U937 lymphoma cells. Br. J.
Cancer, 67, 693-700.
JONKHOFF AR, VAN DIEREN EB, HUIJGENS PC, VERSTEEGH RT,
DRAGER AM, vD LOOSDRECHT AA AND TEULE GJJ. (1994).
Biological effectiveness of 67-Gallium decay in HL60 cells com-
pared with external low dose rate gamma irradiation: effects on
proliferation, G2-arrest and clonogenic capacity. Int. J. Radiat.
Oncol. Biol. Phys., 30, 117-124.
JONKHOFF AR, HUIJGENS PC, VERSTEEGH RT, VAN LINGEN A,
OSSENKOPPELE GJ, DRAGER AM AND TEULE GJJ. (1995).
Radiotoxicity of 67-Gallium on myeloid leukaemic blasts.
Leukaemia Res., 19, 169-174.
KAMINSKI MS, ZASADNY KR, FRANCIS IR, MILIK AW, ROSS CHW,
MOON SD, CRAWFORD SM, BURGESS JM, PETRY NA, BUT-
CHKO GM, GLENN SD AND WAHL RL. (1993). Radioim-
munotherapy of B-cell lymphoma with ['3']anti-BI (anti-CD20)
antibody. N. Engl. J. Med., 329, 459-465.
KELSEN DP, ALCOCK N, YEH S, BROWN J AND YOUNG CH. (1980).
Pharmacokinetics of Gallium nitrate in man. Cancer, 46,
2009-2013.
LARSON SM, ALLEN DR, RASEY JS AND GRUNBAUM Z. (1978).
Kinetics of binding of carrier-free Ga-67 to transferrin. J. Nucl.
Med., 19, 1245-1249.
LEEUWEN-STOCK, VAN AE, DRAGER AM, SCHUURHUIS GJ,
PLATIER AWJ, TEULE GJJ AND HUIJGENS PC. (1993). Gallium-
67 in the human lymphoid cell line U-715: uptake, cytotoxicity
and intracellular localization. Int. J. Radiat. Biol., 64, 749-759.
MAKRIGIORGOS G, ADELSTEIN SJ AND KASSIS AI. (1990). Auger
electron emitters: insight gained from in vitro experiments.
Radiat. Environ. Biophys., 29, 75-91.
NATIONAL COUNCIL ON RADIATION PROTECTION AND MEA-
SUREMENTS. (1970). Precautions in the Management of Patients
who have Received Therapeutic Amounts ofRadionuclides, NCRP
report no. 37. National Council on Radiation Protection and
Measurements: Washington, DC.
NELSON B, HAYES RL, EDWARDS CL, KNISELEY RM AND AND-
REWS GA. (1972). Distribution of gallium in human tissues, after
intravenous administration. J. Nucl. Med., 13, 92-100.
PLAIZIER MABD, ROOS JC, TEULE GJJ, VAN DIEREN EB, DEN HOL-
LANDER W, HAISMA HJ, DEJAGER RL AND VAN LINGEN A.
(1994a). Comparison of non-invasive approaches to red marrow
dosimetry for radiolabelled monoclonal antibodies. Eur. J. Nucl.
Med., 21, 216-222.
PLAIZIER MABD, ROOS JC, VAN DIEREN EB AND TEULE GJJ.
(1994b). Radionuclide therapy and the influence of activity dist-
ribution on bone marrow dose (abstract). Eur. J. Nucl. Med., 21,
984.
PRESS OW, EARY JF, APPELBAUM FR, MARTIN PJ, BADGER CHC,
NELP WB, GLENN S, BUTCHKO G, FISHER D, PORTER B, MAT-
THEWS DC, FISHER LD AND BERNSTEIN ID. (1993). Radio-
labeled-antibody therapy of B-cell lymphoma with autologous
bone marrow support. N. Engl. J. Med., 329, 1219-1224.
RAO DV AND HOWELL RW. (1993). Time-dose-fractionation in
radioimmunotherapy: implications for selecting radionuclides. J.
Nucl. Med., 34, 1801-1810.
ROHATINER AZS AND LISTER TA (eds). (1990). The treatment of
acute myelogenous leukaemia. In: Leukaemia, 5th edn. p. 485.
WB Saunders: Philadelphia.
ROSEN ST AND KUZEL TM. (eds). (1993). Immunoconjugate therapy
of hematological malignancies. Kluwer: Dordrecht, The Nether-
lands.
SCHWARTZ MA, LOVETT DR, REDNER A, FINN RD, GRAHAM MC,
DIVGI CR, DANTIS L, GEE TS, ANDREEFF M, OLD LJ, LARSON
SM AND SCHEINBERG DA. (1993). Dose-escalation trial of M195
labelled with Iodine 131 for cytoreduction and marrow ablation
in relapsed or refractory myeloid leukaemia. J. Clin. Oncol., 11,
294-302.
SEPHTON R AND MARTIN JJ. (1980). Modification of distribution of
gallium 67 in man by administration of iron. Br. J. Radiol., 53,
572-575.
SHANI J. (1986). Drugs that alter biodistribution and kinetics of
radiopharmaceuticals. In: Fourth International Radiopharmaceu-
tical Dosimetry Symposium. Schlafke-Stelson AT and Watson EE
(eds). Proceedings of a conference held at Oak Ridge (TN); 5-8
November 1985. pp. 299-300.
SIEGEL JA, WESSELS BW, WATSON EE, STABIN MG, VRIESENDORP
HM, BRADLEY EW, BADGER CC, BRILL AB, KWOK CS, STICK-
NEY DR, ECKERMAN KF, FISHER DR, BUCHSBAUM DJ AND
ORDER SE. (1990). Bone marrow dosimetry and toxicity for
radioimmunotherapy. Antibody Immunoconj. Radiopharmacol., 3,
213-233.
TANSWELL P AND KOUP J. (1993). Topfit: a PC-based pharmaco-
kinetic/pharmacodynamic data analysis program. Int. J. Clin.
Pharmacol. Ther. Toxicol., 31, 514-520.
VALLABHAJOSULA SR, HARWIG JF, SIEMSEN JK AND WOLF W.
(1980). Radiogallium localization in tumors: blood binding and
transport and the role of transferrin. J. Nucl. Med., 21, 650-656.
VAN DIEREN EB. (1993). Dosimetry of Radionuclides Applicable for
Cancer Therapy, Based on Distance Histogram Techniques
(Thesis). Free University, Amsterdam, The Netherlands.
WATSON EE AND STABIN M. (1984). Basic alternatives software
package for internal radiation dose calculations. In: Computer
Applications in Health Physics, Kathren RL, Higby DP and
McKinney MA (eds) pp. 4.49-4.58, Proceedings of the 17th
Midyear Topical Symposium of the Health Physics Society; Rich-
land, Washington, Columbia Chapter, HPS.